L ike other members of the herpes virus family, human CMV (HCMV) 3 causes a latent infection that can be reactivated under certain circumstances, such as during immune suppression after lung transplantation. HCMV infection is the single most common viral infection following lung transplantation, affecting more than half of the patients and representing one-third of all posttransplantation infections (1) .
NK cells play a major role in combating herpes virus infections both in humans (2, 3) and in mice (4, 5) . These cells constitute ϳ15% of human PBLs, are cytolytic, and have the capacity to produce a number of mainly proinflammatory cytokines. IFN-␥ produced by NK and T cells is important to limit murine CMV (MCMV) and HCMV infection (6 -8) . The activity of NK cells is dependent on signaling through activating and inhibiting receptors, many of which interact with MHC class I molecules. One family of immune regulating receptors, leukocyte Ig-like receptor (LIR)/ immunoglobulin-like transcript (ILT)/monocyte/macrophage Igrelated receptor (MIR), are expressed by NK cells, T cells, B cells, monocytes, and dendritic cells (9, 10) . LIR-1/ILT2/CD85j/ LILRB1, which contains in its intracellular domain four ITIMs, has a broad recognition pattern for classical MHC class I (HLA-A, -B, -C), and nonclassical MHC class I (HLA-G).
In addition to NK cells, CD8 ϩ T cells and to a lesser extent CD4 ϩ T cells are crucial for control of both MCMV (11) and HCMV infection (12, 13) . To evade immune responses, HCMV down-modulates HLA class I molecules on the surface of infected cells thereby reducing T cell recognition (14) . Interestingly, the HCMV-encoded MHC class I-like protein UL18 (15) shows a Ͼ1000-fold higher affinity to LIR-1 compared with cellular MHC class I molecules (9, 16 ). The extremely high-binding affinity of UL18 to LIR-1 suggests that the interaction between these molecules may be a strategically important mechanism for the survival of HCMV in its host. Possible relevance for this interaction is shown by a high expression of LIR-1 especially on HCMV-specific T cells (17, 18) and on lymphocytes in lung-transplanted patients before development of CMV disease (19) .
Data regarding the impact of UL18 on NK cell function are controversial: the MHC class I homolog seems to inhibit NK cellmediated lysis in certain experimental settings (20, 21) , but not in others (22, 23) . Concerning T cells and UL18, there is one report (24) proposing that UL18 stimulates CD8
ϩ T cell killing of infected cells via triggering of LIR-1, while many publications indicate the contrary, i.e., that LIR-1 engagement inhibits T cell function (25) (26) (27) (28) .
In this study, we focused on the role of LIR-1 in the immune response to CMV, and potential functions of UL18. We addressed three questions: 1) which subsets of lymphocytes augment the LIR-1 expression previously observed early in lung transplant patients? 2) How is the LIR-1 expression induced-are cytokines involved, is it a consequence of interaction with virus infected cells? 3) Is there a functional consequence of LIR-1 expression in relation to the virally encoded ligand UL18?
Materials and Methods

Subjects
Thirteen consecutive patients (median age, 56 (30 -65) years) undergoing single lung (n ϭ 11), bilateral lung (n ϭ 1), or heart lung (n ϭ 1) transplantation from March 2000 to February 2001 were studied. For comparison, blood samples from five healthy subjects (median age, 29 (29 -37) years) were collected monthly. CMV disease was defined as symptoms of pneumonitis combined with presence of CMV inclusion bodies in transbronchial biopsy and/or bronchoalveolar lavage (BAL) samples following the criteria for CMV disease of the Fourth International Cytomegalovirus Workshop (29) . The patients were divided into those who developed CMV disease during the study (CMVd ϩ ) and those who did not (CMVd Ϫ ). Surveillance bronchoscopy with transbronchial biopsy and BAL was performed at 2, 4, 8, 12, 18, and 24 wk after transplantation. The clinical characterization and treatment of the patients has been described earlier (19) .
For in vitro studies of lymphocyte function, buffy coats from healthy blood donors and laboratory personnel were included.
Collection of samples
Blood was drawn before bronchoscopy. PBMC were separated and frozen in FCS plus 10% DMSO at Ϫ70°C. BAL was performed by infusing PBS into a segmental middle lobe or lingula bronchus. Cellular components were frozen in FCS plus 10% DMSO at Ϫ70°C for later analysis. All cell samples from each patient were thawed and stained at the same time.
Quantitative HCMV PCR analysis
HCMV DNA in serum (copies per milliliter) was quantified using the Roche Cobas Amplicor HCMV Monitor (CMM) system according to the manufacturer's instructions. One HCMV low-positive control, one HCMV high-positive control, and one HCMV-negative control were included in each experimental run. The limit of detection was 400 copies/ml (30) To avoid effects of between-assay variation, all samples from each patient were run in parallel in the same test session.
Analysis of cell surface molecule expression
Abs used were: PerCP-or allophycocyanin-conjugated anti-CD3 (BD Biosciences), allophycocyanin-or FITC-conjugated anti-CD56 (BD Biosciences), Abs to LIR-1 (M405) (31), UL16 binding protein (ULBP) (M-295), ULBP2 (M-311), ULBP3 (M-551), MHC class I polypeptiderelated sequence (MIC)A (M-673), MICB (M-362) (provided by Amgen), ICAM-1 (BD Biosciences), and poliovirus receptor (PVR) (Abcam) in combination with PE-conjugated goat anti-mouse IgG (DakoCytomation). PE-conjugated anti-LIR-1 (HP-F1; Beckman Coulter), PE-conjugated anti-CD69 (DakoCytomation), PE-conjugated anti-Nectin-2 (BD Biosciences), allophycocyanin-conjugated anti-CD4, and anti-CD8 (BD Biosciences), FITC-conjugated (FabЈ) 2 goat antihuman IgG1 (Jackson ImmunoResearch Laboratories Europe) for UL18Fc detection and allophycocyanin-labeled anti-mouse IgG1 (BD Biosciences) for detection of M405 and HP-F1 (anti-LIR-1 mAb, provided by Dr. M. Lopez-Botet, Universitat Pompeu Fabra, Barcelona, Spain). Mouse IgG1 was used as negative control for unconjugated Abs, UL16Fc as control for UL18Fc. For virally induced expression of FcRs, fibroblasts were stained with normal human serum and FITC-conjugated (FabЈ) 2 goat anti-human IgG1. The lymphocyte gate was confirmed by gating on CD3 ϩ cells.
Viruses
HCMV strains used were AD169, the UL18 deletion mutant of AD169 (a gift from H. Browne, University of Cambridge, Cambridge, U.K.) and the clinical strain 4636. Virus was propagated on human embryonic lung (HL) fibroblasts purchased from the Swedish Institute for Infectious Disease Control, batched, and stored at Ϫ70°C. Viral titers were determined by plaque assays as described (32 Alternatively, PBMC, T cells, or NK cells were added in same numbers as above day 3 p.i. and cultures were incubated overnight before addition of GolgiStop (BD Biosciences) at a dilution of 1/1500. After additional 4-h incubation, surface staining for CD3, CD56, and LIR-1/CD85j (Beckman Coulter) was performed. Intracellular staining of IFN-␥ was done using Ab from clone 4S.B3 (BD Biosciences). For blockade of LIR-1-UL18 interactions, the purified UL18 mAb 10C7 at 10 g/ml (hybridoma purchased from American Type Culture Collection) and 5% human serum was added to the fibroblasts 30 min before addition of PBMC.
Stimulation of T cells through CD3 in combination with LIR-1
PBMC or negatively isolated T cells prestimulated overnight with 50 U/ml IL-2 were stimulated with anti-CD3 mAb OKT3 (in-house production) on precoated PolySorp plates (Nunc; 1,5 ϫ 10 5 cells/well). For costimulation/ inhibition, wells were coated with 0.6 g/ml OKT3 in combination with 10 g/ml anti-CD28, UL16Fc protein (provided by Amgen) or UL18Fc fusion protein (plasmid provided by D. Cosman, Amgen). UL18Fc protein was produced in 293FT cells (Invitrogen Life Technologies) as described (33) . GolgiStop was added after 40 min. Samples were incubated for an additional 4.5 h before surface staining and staining for intracellular IFN-␥ was performed as described above.
Statistics
Differences between patients groups were analyzed using Mann-Whitney and changes within patients over time using Wilcoxon signed rank Test. The Student paired t test or ANOVA analysis with subsequent NewmanKeuls multiple comparison test were used as indicated in figure legends. Graphs depict mean Ϯ SEM or mean Ϯ SD, as indicated in figure legends. Statistical significance was set to p Ͻ 0.05.
Results
Increased LIR-1 expression on blood NK and T cells before HCMV diagnosis
We previously reported an early increase in the percentage of blood lymphocytes expressing LIR-1 in patients that later developed CMV disease (CMVd ϩ patients) (19) . This augmented LIR-1 expression was evident before detection of CMV by PCR. The herein reported analysis of subsets showed that the increase in LIR-1 expression was most evident on NK cells (CD3 Ϫ CD56 ϩ , Fig. 1a ), reaching significant differences between CMVd ϩ and CMVd Ϫ patients early after transplantation (at weeks 4 and 8, p ϭ 0.02 and 0.02, respectively). The increased expression of LIR-1 was also evident on CD3 ϩ CD56 ϩ T cells (Fig. 1b , p ϭ 0.02 at weeks 8 and 24) and on CD3 ϩ
CD56
Ϫ T cells (Fig. 1c , p ϭ 0,05 at week 2, p ϭ 0,004 at week 8, and p ϭ 0,02 at week 24). We could not detect a change over time in the level of LIR-1 expression on monocytes as measured by median fluorescence intensity (MFI), nor a difference between the patient groups (data not shown).
The proportion of T cells and NK cells within the lymphocyte gate did not differ between patient groups and decreased by approximately half and by a factor of seven, respectively, due to induction treatment. The proportion of T cells recovered to normal levels at week 8 (data not shown).
The early increase of the percentage of NK cells expressing LIR-1, from Ͻ8% before transplantation to Ͼ20% at week 2, was seen in all CMVd ϩ patients ( Fig. 1d ) and only in one CMVd Ϫ patient ( Fig. 1e ). This particular CMVd Ϫ patient (Fig. 1e , E) was the only CMV-seronegative patient receiving an organ from a sero-positive donor. One patient who developed CMV disease never showed detectable virus levels in serum (Fig. 1d, E) . However, also this patient showed an increase in LIR-1 expression. Another patient, who did not develop CMV disease but who had HCMV DNA in serum (380 copies of virus/ml) at week 12 ( Fig.  1e, triangle) , showed an increase in LIR-1 ϩ cells week 12. Data from before transplantation and weeks 2 and 4 following transplantation are missing for this particular patient because there were not enough lymphocytes for a reliable analysis.
Induction of LIR-1 on NK cells
As factors regulating the expression of LIR-1 on NK cells are unknown, possible mechanisms for the observed induction of LIR-1 in CMVd ϩ patients were investigated. First, we investigated whether cytokines were produced locally in the lung in CMVd ϩ patients analyzing BAL fluid by ELISA. We could detect IL-15 in six of eight CMVd ϩ patients (median: 85, range: 51-308 pg/ml) and in two of five CMVd Ϫ patients (51 and 101 pg/ml), but the difference between patient groups did not reach statistical significance. Low cell numbers impeded the investigation of LIR-1 expression on lymphocytes from BAL fluid.
As IL-15 was found in BAL fluid of CMVd ϩ patients and is important in NK cell proliferation in mouse CMV infection (34), we studied the effect of IL-15 on LIR-1 expression by healthy control PBMC in vitro. We also included IL-2, known to induce LIR-1 expression on activated CD8 ϩ memory T cells (26) , and IL-10, because HCMV encodes a IL-10 homolog (35) . LIR-1 was found to be predominantly expressed by the CD56 dim NK cell subset in peripheral blood and incubation of PBMC with IL-15 or with IL-2 increased the percentage of LIR-1-expressing NK cells by ϳ20% (data not shown). Also IL-10 slightly affected LIR-1 expression on NK cells, while TGF-␤ had no effect (data not shown). In vitro BrdU incorporation indicated that the increased frequency of LIR-1-expressing NK cells upon cytokine stimulation was not due to specific proliferation of LIR-1-expressing cells, but rather induction of LIR-1 on previously LIR-1 Ϫ NK cells. The percentage of LIR-1 ϩ T cells did not change upon cytokine stimulation (data not shown).
To assess the possibility that virus infected cells can induce LIR-1 up-regulation on NK cells and/or T cells, PBMC from healthy donors were cocultured with uninfected or infected HL fibroblasts from days 3 to 5 p.i. The incubation time was chosen to allow even late viral transcripts like UL18 to be sufficiently expressed while infected fibroblasts were still viable. The clinical strain 4636 was included to detect a possible role of UL18 on LIR-1 regulation, because the 4636 strain encodes a UL18 protein with higher affinity for LIR-1 than AD169 (36) . There was no consistent effect on the expression of LIR-1 on NK cells, neither in percentage of cells nor in level of expression (MFI) in this setting, using AD169-infected HL (Fig. 2a) or the clinical strain 4636 (Fig.  2b) . Among the donors, four were seropositive for HCMV, and these showed no change or even a decreased percentage of LIR-1-expressing NK cells. NKG2C, NKp44, and NKp46 were other markers that were not significantly changed in the cocultures. Yet, all donors showed a dramatic increase in NK cells positive for the activation marker CD69 when cultured with infected fibroblasts (Fig. 2c) . CD69 was also up-regulated on T cells (data not shown). LIR-1 expression on T cells was not affected by the 2-day coculture with virus infected HL, neither the percentage of positive cells nor MFI (data not shown).
Reduced cytokine production of PBMCs in response to dUL18 compared with AD169-infected fibroblasts
To investigate the role of LIR-1/UL18 interactions during activation of NK and T cells, we used AD169-infected fibroblasts or fibroblasts infected with a deletion virus for UL18 (dUL18) created on the AD169 background (37) . We set up cocultures of PBMC from healthy donors and infected fibroblasts. Supernatants were analyzed by ELISA and were found to contain considerable levels of IFN-␥ and IFN-␣ (Fig. 3) . It is likely that Ag-experienced effector cells participate in the IFN-␥ response to HCMV-infected fibroblasts, because seronegative donors, despite having substantial frequencies of LIR-1-expressing T cells, displayed only a minor IFN-␥ response (Ͻ2 ng/ml, data not shown). This indicates that the IFN-␥ response was not solely induced by UL18-LIR-1 interaction as reported for triggering of cytotoxicity in CD8 ϩ T cells (24) . Other contributing factors, either TCR-dependent or bystander effects (38) should be involved. Surprisingly, the deletion of UL18 reduced both IFN-␥ and IFN-␣ levels significantly (Fig.  3a) . Virus-infected fibroblasts produced no detectable IFN-␣ and uninfected fibroblasts coincubated with PBMC induced IFN-␥ levels Ͻ1 ng/ml and no detectable IFN-␣.
To dissect the role of different cell types for the IFN-␥ response to infected fibroblasts, PBMC or separated cultures of either T cells, NK cells, combined NK plus T cells or CD14-depleted PBMC were cultured as above with AD169-or dUL18-infected HL (Fig. 3b) . Isolated T cells produced low levels of IFN-␥ during culture with AD169-infected HL and significantly less in absence of UL18. A combination of purified NK and T cells augmented levels of IFN-␥, while the trend for less production with dUL18 was maintained. NK cells alone did not produce detectable levels of IFN-␥ (Fig. 3b) . Monocyte depletion decreased IFN-␥ levels compared with PBMC, while the dUL18 trend was still discernable. We conclude that T cells alone can produce IFN-␥ in response to virus-infected cells, while monocytes and NK cells augment cytokine production. The reduced ability of dUL18-infected fibroblasts to induce IFN-␥ is seen also using isolated T cells, indicating that UL18, or other nearby viral genes, may have an activating effect on T cells.
To ensure that the difference in cytokine response to dUL18 compared with AD169 was not due to different efficiency of infection, several control experiments were performed. Viral titers were determined by plaque assays, infectivity was monitored by microscope, different batches of viruses were used, and virus was titrated to determine the range of MOI where cytokine response was constant (data not shown). Furthermore, infected fibroblasts were stained intracellularly for the virally encoded protein UL44 to measure infection level (Fig. 3c) .
Both LIR-1 ϩ and LIR-1 Ϫ NK cells contribute substantially to IFN-␥ production in cocultures
Because the only known receptor for UL18 is LIR-1, we wanted to relate cytokine production to cell type and LIR-1 status. Intracellular staining for IFN-␥ was performed on PBMC cocultured with infected fibroblasts (AD169 or dUL18, Fig. 4) .
In coculture of bulk PBMC with infected fibroblasts, T cells and NK cells contributed equally in absolute numbers (data not shown) to the IFN-␥ ϩ cell fraction. Among T cells, the majority of IFN-␥-producing cells were LIR-1 ϩ (Fig. 4) , in line with previously published observations that couple the expression of LIR-1 to virus-specific T cells with an effector memory phenotype (18, 39) . No significant decrease in the percentage of IFN-␥ ϩ T cells in PBMC upon contact with dUL18-infected HL compared with AD169 was detectable in this setup, reflecting a decreased production of IFN-␥ per T cell rather than a decreased proportion of T cells responding dUL18 (Fig. 3) . However, NK cells of both LIR-1 ϩ and LIR-1 Ϫ subsets showed a reduced response to dUL18-infected fibroblasts compared with AD169, and LIR-1 status had no impact on IFN-␥ production (Fig. 4) . Only a very small fraction of isolated T cells stained positive for IFN-␥ after contact with infected fibroblasts, and isolated NK cells did not respond at all (data not shown). A combination of NK and T cells resulted surprisingly in IFN-␥ production by NK cells only (data not shown), indicating that the IFN-␥ produced by NK cells in response to infected cells is T cell dependent and that the IFN-␥ detected by ELISA in supernatants of NKϩT cells (Fig. 3b) is mostly produced by NK cells. 
UL18Fc fusion protein reduces T cell IFN-␥ production
We wanted to study the direct effect of UL18 on T cells in an isolated setup using UL18Fc fusion proteins, because PBMC cultured with infected fibroblasts produced less IFN-␥ in the absence of UL18 compared with wild-type AD169-infected HL (Fig. 3, a  and b) , and because IFN-␥ production by T but not NK cells was LIR-1 dependent (Fig. 4) and T cells were involved in triggering NK cell responses to infected cells (data not shown).
It was first determined whether the UL18Fc proteins bound exclusively to LIR-1 expressing T cells (Fig. 5a ). T cells were stained with UL18Fc and conjugated secondary Ab (Fig. 5a, left  panel) , with anti-LIR-1/CD85j-PE (Fig. 5a, middle panel) or with the combination of the two (Fig. 5a, right panel) . To account for possible Fc binding, UL16Fc was used as control and found not to stain (data not shown). Fig. 5a illustrates that UL18Fc recognized only LIR-1 ϩ T cells, and because staining with both reagents create a diagonal staining profile, it is probable that UL18Fc and the anti-LIR-1 Ab stain the same protein. Furthermore, the data show that the binding of UL18Fc could not block the epitope for this Ab (clone HP-F1).
Intracellular IFN-␥ production was measured to assess the impact of UL18Fc binding to LIR-1 during T cell stimulation by anti-CD3 (OKT3) with and without costimulation through CD28 (Fig. 5, b-d ). Suboptimal stimulation with OKT3 induced IFN-␥ production mainly by LIR-1 ϩ T cells. This response was markedly reduced by addition of UL18Fc, but not UL16Fc (Fig. 5, b and c) . Engagement of the costimulatory molecule CD28 resulted in increased IFN-␥ production in both LIR-1 ϩ and LIR-1 Ϫ T cells (Fig.  5c ). UL18Fc almost completely blocked also the costimulated induction of IFN-␥ production by LIR-1 ϩ T cells in all donors, while there was no such effect by UL16Fc. Similar results were obtained using bulk PBMC from seropositive donors (Fig. 5d) . A certain degree of blocking was also seen for UL16Fc and UL18Fc proteins in LIR-1 Ϫ T cells in some donors. This effect could be a contribution by the Fc portion or unspecific protein competition during coating. It was not possible to block the UL18Fc effect by including the LIR-1 Ab HP-F1 in the assay, because this Ab was found to bind to a different epitope on LIR-1 (Fig. 5a and data not  shown) .
In our setup, the frequency of LIR-1 ϩ T cells of healthy blood donors was higher on CD8 ϩ T cells (12.7 (4.2-63.5%)) compared 
with CD4
ϩ T cells (3.2 (0.5-18.5%), p ϭ 0,02), corroborating previous publications (17, 39) . Nevertheless, LIR-1 ϩ CD4 ϩ T cell constituted a substantial subset in most donors and results obtained when gating on CD8 ϩ or CD8 Ϫ T cells separately did not differ from results described above (data not shown).
UL18Fc protein decreases IFN-␥ production in PBMC-HL cocultures but cannot abrogate the difference between AD169 and dUL18
In line with previous results (40), we were not able to stain by flow cytometry for surface-expressed UL18 on AD169-infected HL using the 10C7 mAb (41), while fibroblasts infected with recombinant vaccinia virus expressing UL18 were clearly stained with this Ab (data not shown). Neither did we observe a difference between AD169-or dUL18-infected HL when staining with LIR-1Fc proteins (data not shown). In contrast, UL18 expression was clearly detected by Western blot using the anti-UL18 mAb M71 (Amgen), either on whole cell lysates of AD169-infected cells (and dUL18 as control) or after immunoprecipitation of cell lysates with 10C7 (data not shown). The lack of detectable surface UL18 on AD169-infected HL argues against a direct interaction between LIR-1 on leukocytes and viral UL18. However, UL18 could be expressed in amounts below detection limit of our method. To further investigate a possible interaction of LIR-1 and viral UL18, we added UL18Fc, or UL16Fc as control, to cocultures of PBMC and HL infected with AD169 or the UL18 deletion virus. The amount of IFN-␥ detected in the supernatant of such cocultures was decreased substantially in presence of UL18Fc, but not in presence of UL16Fc, for both viral strains (Fig. 6, a and b) . The inhibitory effect of UL18Fc in both viral cultures recapitulates the strong reduction of cytokine production by UL18Fc observed in experiments with OKT3 stimulated T cells (Fig. 5, b and d) . It is likely that FcRs expressed on leukocytes and on infected fibroblasts account for cross-linking of UL18Fc bound to LIR-1 in the cocultures. Thus, addition of UL18Fc proteins did not merely block a possible interaction of low-level surface expressed viral UL18 with LIR-1, but mainly led to inhibition by triggering LIR-1. It is noteworthy that despite the general inhibitory effect of UL18Fc proteins in PBMC-HL cocultures, the significant difference in IFN-␥ production upon contact with AD169-or dUL18-infected HL persisted (Fig. 6c) .
Instead of using UL18Fc, the addition of anti-UL18 Ab 10C7 to the same coculture setup should only disrupt binding of potential surface expressed UL18 and LIR-1. However, the use of 10C7 could not abrogate the difference in cytokine response induced by dUL18 compared with AD169-infected HL (data not shown).
Changes in cell surface molecules on infected HL cannot explain the different cytokine response to AD169-or dUL18-infected cells
Our interpretation of the presented data is that a potential interaction between LIR-1 and UL18 expressed by virally infected cells has at best a minor effect on leukocyte function, while the increased cytokine production seen in response to AD169 infected fibroblasts may be due to some as yet unidentified, possibly intracellular, function of UL18. To test whether UL18 interferes with expression of ligands for NK and T cells on infected fibroblasts, cells were stained for MHC class I, MICA, MICB, ULBP1-3, PVR, Nectin-2, and ICAM-1 (Fig. 7) . HCMV infection induced expression of FcRs, ULBP1, 2, 3 (42), MICA, B (43), ICAM-1 (44), PVR and Nectin-2, while class I levels were decreased (45) . Expression of ULBP1/2 and Nectin-2 were slightly more elevated on dUL18 compared with AD169-infected fibroblasts, whereas expression levels of the other molecules did not differ between viral strains (Fig. 7) . The observed slight increase in expression of activating NKR ligands on dUL18-infected fibroblasts cannot explain the decrease in cytokine induction.
Discussion
We have in this study extended our previously published findings of an increased expression of LIR-1 on lymphocytes following lung transplantation in patients that later develop CMV disease (19) . We herein report that the increased LIR-1 expression is most clearly seen on NK cells and is also evident on T cells. Coculture with virus infected fibroblasts induced IFN-␥ secretion by LIR-1 during such coculture. On the contrary, isolated UL18Fc fusion protein could inhibit IFN-␥ production of anti-CD3-activated T cells. Possible explanations for the described LIR-1 induction in lungtransplanted patients include HCMV-dependent and -independent events. Two-day cocultures of PBMC with infected fibroblasts did not up-regulate frequencies (Fig. 3) or expression levels (data not shown) of LIR-1 ϩ NK or T cells, while anti-CD3 stimulation has been shown to enhance numbers of LIR-1 ϩ T cells after 2 days (25) . Another study (46) has reported an increase in the proportion of LIR-1-expressing T cells after 10 days coculture with HCMVinfected fibroblasts. This up-regulation was seen also after coculture with fibroblasts infected with UV-irradiated virus or addition of virus without fibroblasts to PBMCs, pointing toward specific T cell activation rather than molecular interactions between LIR-1 and UL18 as reason for induction of LIR-1. In our hands, LIR-1 was only slightly up-regulated on T cells cocultured with infected fibroblasts day 3-11 p.i. compared with uninfected fibroblasts, and LIR-1 expression by NK cells was not consistently affected under these circumstances (data not shown).
In contrast, our results are consistent with the possibility that NK cells are induced to express LIR-1 by exposure to cytokines produced locally in the lung. Although three of the eight CMVd ϩ patients showed Ͼ150 pg IL-15/ml BAL fluid on at least one occasion (and none of the five CMVd Ϫ patients), the difference between the groups was not significant. The results therefore do not allow us to conclude whether local IL-15 levels were responsible for the differences in LIR-1 expression and additional factors in the CMVd ϩ patients (e.g., early undetectable reactivation of HCMV) can play a role. The question thus remains: is the increase in LIR-1 expression the consequence of early HCMV reactivation, or does it precede and predispose to it. In the latter case, one may speculate that the LIR-1 induction can be more prominent in some patients due to genetic-or disease-associated factors, and this early strong LIR-1 up-regulation may subsequently down-modulate immune reactions through cognate MHC ligands and to a limited extend contingently also through interactions with viral UL18. This would then contribute to immunosuppression leading to HCMV reactivation and disease.
To study the direct effect of UL18 on T cells, we used UL18Fc proteins and observed reduced IFN-␥ production upon stimulation of T cells via the TCR in the presence of UL18. One previous report shows that UL18 can induce CD8 ϩ T cell lysis of HCMVinfected cells or cells infected with vaccinia virus expressing UL18 in a MHC class I/TCR independent manner (24) . Yet the mechanism by which the inhibitory receptor LIR-1 can deliver activating signals remains to be elucidated. In contrast, the same group and others have demonstrated that engagement of LIR-1 can inhibit CD8 ϩ T cell cytokine production (25) (26) (27) and in some (26, 28) , but not all (25) , settings also cytotoxicity.
However, our data obtained with the UL18 deletion virus argue against the simple notion that UL18 acts to inhibit the immune response. IFN-␥ and IFN-␣ responses were diminished when PBMC or purified T cells were cocultured with fibroblasts infected with UL18 deletion virus compared with the parental strain AD169, a rather surprising finding considering the inhibitory functions of the UL18R LIR-1 (25, 27, 31, 47, 48) . Other studies using dUL18 virus to detect a potential inhibitory effect of UL18 on NK cells also observe rather an enhancement of killing instead of inhibition (22, 23) . One possible explanation is that UL18 binds to another unknown receptor on NK or T cells. Costaining of T cells with anti-LIR-1 Ab and UL18Fc protein resulting in an exact overlapping T cell subset (Fig. 5) as well as immunoprecipitations with UL18 and LIR-1 on CD8
ϩ T cells (24) argue against this hypoth-
esis. Yet, UL18 may have other ligands on monocytes or dendritic cells, or alternatively, ligation of LIR-1 on those cells may result in enhanced effector functions of T and NK cells via cell crosstalk. In contrast, as isolated T cells responded similarly compared with T cells in PBMC bulk cultures (Figs. 3b and 5, c and d) , the involvement of other LIR-1 expressing cell types in the culture is not a prerequisite. A third possibility is that UL18 interacts intracellularly with either cellular or other viral proteins, leading to an altered expression of surface molecules on infected cells that in turn influence immune responses to HCMV. This scenario could explain why studies on the effect of UL18 on NK cells using UL18 expressed in isolation (20, 21) reach other conclusions compared with studies with HCMV-infected cells (22, 23) . The lack of detection of UL18 surface expression on infected fibroblasts by flow cytometry (data not shown and Ref. 40) as well as the failure to abrogate the difference in cytokine response toward AD169 and dUL18 by addition of either UL18Fc proteins (Fig. 6c) or the anti-UL18 Ab 10C7 (data not shown) point toward an intracellular role of UL18. In summary, our data indicate that the net effect of UL18 expressed in infected cells does not inhibit, but rather activate NK and T cell function. We speculate that UL18 may have as yet unidentified effects regulating immune responses, possibly by inhibition of negative regulatory pathways, leading to a more potent activation of lymphocytes. As to LIR-1, one must also consider the possibility that increased expression can lead to a general inhibition via interaction with MHC class I molecules, thus explaining the observed connection between elevated LIR-1 expression and CMV disease.
